On the first point from the quarterly filing, ("results of the nine months are not necessarily indicative in relationship to their flexible summary of General Revenue") --


Certain placements have more that one cardiac theater -- Mayo at Rochester and St. David's (U.Texas - Austin) as two prime examples.

To offer generous terms that puts your new product into the skilled hands of premier heart rhythm clinicians within key US markets ... makes for a brilliant introduction, vis 'a vis Marketing 101. As the leaders go, so shall others follow. For St. David, I would write off the units, giving them away for free for all three sites, just for the KOL leadership impact of Dr. Natalie.

As fluid as their published GENERAL TERMS appear to be, management could pull off a 4Qtr major revenue upside for placements in the early part of the year. Absent a major 4Q bump, imo, it is proper and logical to question how this year's first 12 placements (say, through May), could generate less than $500 thousand. Some degree of transparency on pricing strategy would be appropriate as explanation. After all, its not like the micro-frequency innovation is still hidden from competition under a bushel basket. All of the rhythm majors took note of July's unblinding data.

Just an upbeat possibility of sunshine. I'll be holding hope for the culminating measure and/or candor on or before February 14th. All the best.